Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Milei Threatens Falkland Oil Firms With Sanctions 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Add as a preferred source on Google
SAN DIEGO, Feb. 27, 2018 -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, will release its fourth quarter and full year 2017 financial results after the market closes on Tuesday, March 13, 2018 followed by a conference call at 4:30 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review financial results and discuss other business matters.
The conference call dial-in numbers are (855) 765-5682 for domestic callers and (919) 825-3204 for international callers. The conference ID number for the call is 7392256. Participants may access the live webcast via a link on the Vital Therapies website in the Investors Relations section under Events at: http://ir.vitaltherapies.com/. The webcast will be archived on the Company's website shortly after completion of the call.
For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 7:30 p.m. ET on March 13, 2018 to 7:30 p.m. ET on March 20, 2018. The conference call replay numbers for domestic and international callers are (855) 859-2056 and (404) 537-3406, respectively. The conference ID number for the replay is 7392256.
Upcoming Investor Conference
Additionally, the Company will be presenting at the Raymond James 39th Annual Institutional Investors Conference Orlando, FL on Monday, March 5th at 2:15 PM Eastern. A live webcast of the Company's presentation will be available on the Investor Relations page of the Company's website at: http://ir.vitaltherapies.com/. An archive of the presentation will be available for replay following the conference.
About Vital Therapies, Inc.
Vital Therapies, Inc. is a biotherapeutic company developing a cell-based therapy targeting the treatment of acute forms of liver failure. The Company's ELAD System is an extracorporeal human allogeneic cellular liver therapy currently in phase 3 clinical trials. Vital Therapies, Inc. is based in San Diego, California. Vital Therapies® and ELAD® are trademarks of Vital Therapies, Inc.
Contact:
Vital Therapies, Inc.
Al Kildani
Vice President, Investor Relations and Business Development
858-673-6840
[email protected]
